Immunome Inc. (IMNM): Depreciation & Amortization
$2.47M
Year ended 2025-12-31
$2.78M
Trailing 12 months to 2026-06-30
+80.1%
3-year compound annual growth
+26.7%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.47M | +57.4% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $1.57M | +242.9% | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $457.0K | +8.3% | 2025-03-19, From 2023-01-01 |
| 2022-12-31 | $422.0K | -44.1% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $755.0K | 0.0% | 2023-03-16, From 2021-01-01 |
| 2020-12-31 | $755.0K | +22.8% | 2022-03-28, From 2020-01-01 |
| 2019-12-31 | $615.0K | n/a | 2021-03-25, From 2019-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Immunome Inc. (IMNM) | 2025-12-31 | $2.47M | +57.4% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $79.0K | -59.1% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $273.0K | -55.5% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $2.54M | -0.7% |
| Adagene Inc. (ADAG) | 2025-12-31 | $438.9K | -39.3% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $1.29M | -27.5% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $454.0K | -43.7% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $3.35M | -76.2% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $219.0K | +6.3% |
Compare IMNM, WHWK, OVID, XENE side by side · Screen every company in Pharmaceutical Preparations ↗